Schedule a Call Back
Piramal Pharma Solutions expands ADC Manufacturing Facility in Scotland
Industry News- Dec 19,23
Renowned as a global leader in ADC development and manufacturing, Piramal Pharma Solutions has an impressive track record, having developed hundreds of payloads and manufactured over a thousand ADC batches.
Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organisation (CDMO) and a division of Piramal Pharma (PPL), celebrated the inauguration of its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.
Distinguished guests at the ceremony included Adrian Gillespie, Chief Executive of Scottish Enterprise. Representing Piramal were key figures such as Nandini Piramal, Chairperson, Piramal Pharma; Peter DeYoung, CEO, Piramal Pharma Solutions; Herve Berdou, COO, Piramal Pharma Solutions; Chris Leahy, SVP Finance, Piramal Pharma Solutions; and Francois Houbart, Managing Director and Grangemouth Site Head, Piramal Pharma Solutions.
Renowned as a global leader in ADC development and manufacturing, Piramal Pharma Solutions has an impressive track record, having developed hundreds of payloads and manufactured over a thousand ADC batches. The expansion of the facility increases its capacity by approximately seventy to eighty percent, facilitating the scaling up of commercial ADC manufacturing batches. Completed within this fiscal year, the expansion introduces two new ADC manufacturing suites designed to complement the existing three. The £45 million investment was made possible through a combination of a Scottish Enterprise government grant, a bank loan, customer co-investment, and internal accruals.
The primary beneficiaries of this expansion are Piramal's customer base and the patients they serve. The increased capacity supports the site's ability to manage the entire life cycle of ADC development and manufacturing, including ADCelerate™, Piramal's branded solution for the rapid early-stage development of ADC drugs. ADCelerate integrates the development of the monoclonal antibody (mAb), linker/payload, conjugation, and sterile fill/finish into a streamlined program across four global Piramal sites, including Grangemouth. This approach accelerates the development and manufacturing process, expediting the delivery of new compounds to patients.
In addition to the enhanced manufacturing capabilities, the site expansion features a dedicated customer experience centre, new Quality Control laboratories, warehousing, office space, and supporting utilities. The modular construction technology used in the building allows for expedited completion and is designed to accommodate future expansions. Potential future enhancements may include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes.
Peter DeYoung, CEO of Piramal Pharma Solutions, expressed, "The global ADC market is experiencing robust growth, and so is the pipeline at Grangemouth, necessitating additional capacity to meet customer demand. This expansion positions us to cater to further growth and undertake future projects. With the market trending towards large and commercial scale manufacturing, the new facility is well-equipped to address these needs. We have now doubled our ADC production capacity, strengthening our ability to serve customers throughout the entire drug lifecycle."
Adrian Gillespie, Chief Executive of Scottish Enterprise, remarked, "Today's opening marks the culmination of Piramal's significant £45 million investment in Scotland's life sciences sector, creating and safeguarding high-quality jobs. We are delighted that the company chose Scotland as the ideal location for its pioneering work on ADCs – a new and growing area of medical innovation. We look forward to continuing and deepening our relationship with Piramal."
Wellbeing Economy Secretary Neil Gray emphasised, "This £45 million investment in pharmaceutical innovation contributes to Scotland's strengths in health and life sciences, creating new jobs and opportunities as part of a fair and growing wellbeing economy. It also enhances Grangemouth's heritage as a critical manufacturing hub for Scotland."
Secretary Gray added, "Scotland's National Innovation Strategy sets out our vision for becoming one of the most innovative small nations in the world over the next decade, working with partners to grow world-leading excellence in our priority areas."
Source: PR Newswire
Piramal Pharma Solutions
Antibody-Drug Conjugate
CDMO
Pharmaceutical
Scottish Enterprise
ADCelerate
Peter DeYoung
Neil Gray
Related Stories
Other Industrial Products
Piramal Pharma Solutions expands ADC Manufacturing Facility in Scotland
Renowned as a global leader in ADC development and manufacturing, Piramal Pharma Solutions has an impressive track record, having developed hundreds of payloads and manufactured over a thousand ADC ..
Read morePolicy Regulation
PLI scheme: Need for a course correction
The Government of India is reportedly planning to ease some norms for five sectors (textiles, pharmaceuticals, drones, solar and food processing) to help them better utlise the fund under its Produc..
Read moreProcess Equipment
GBA will facilitate access to technology, policy interventions in global south
…opines Dr Pramod Chaudhari, Executive Chairman, Praj Industries in this interview on the declaration of Global Biofuel Alliance at G20 Summit 2023.
Read moreRelated Products
Sautiner Machine
Pharmaceutical Machinery & Accessories
Sree Valsa Engineering Company offers a wide range of
sautiner machine.
Zero Holdup Filter Press
Pharmaceutical Machinery & Accessories
Veena Pharma Machinery offers a wide range of zero holdup filter press.
Single Rotary Tablet Press Machine - Issac Ci 10008
Pharmaceutical Machinery & Accessories
Chamunda Pharma Machinery Pvt Ltd offers a wide range of single rotary tablet press machine - ISSAC Ci 10008 .
latest News
Subscribe to iNoW
For Industry News on WhatsApp, Give a Miss Call on: +91 84228 74016
